SYGNAMAP, INC.
Biotech · Private
MSI-DeepPath: a computational platform that quantifies spatially distinct metabolite abundancies from MALDI mass spectrometry imaging data and correlates them with histopathologic features for biomark
sygnamap.com →- Grants
- $1.6M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · On-chip filtration and fractionation components for high-sensitive POC device to measure Chiral Metabolites in Urine | $307,230 | |
| Federal grant | Department of Health and Human Services · Phase I · Precision Mass Spec Imaging Based Structure-Function Signatures of Diabetic Glomerulopathy | $300,000 | |
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Computational platform to infer putative causative pathways of pathology using spatial omics data | $255,994 | |
| Federal grant | Department of Health and Human Services · Phase I · Precision Mass Spec Imaging Based Structure-Function Signatures of Diabetic Glomerulopathy | $6,500 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Quantitative Normalization of Spatial Metabolomics for Molecular Signatures of Tissue Heterogeneity | $356,499 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Quantitative Normalization of Spatial Metabolomics for Molecular Signatures of Tissue Heterogeneity | $356,499 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3375 | Concerto Biosciences, Inc. | — | $16M |
| 3376 | UNCO THERAPEUTICS LLC | — | — |
| 3377 | Inspira Therapeutics, Inc | — | — |
| 3378 | SYGNAMAP, INC. | — | — |
| 3379 | Polyrizon Ltd. | — | $7.5M |
| 3380 | BlossomHill Therapeutics | — | $246M |
| 3381 | Shattuck Labs, Inc. | — | $164M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.